Literature DB >> 6127012

Antiviral action of dipyridamole and its derivatives against influenza virus A.

E Tonew, M K Indulen, D R Dzeguze.   

Abstract

Dipyridamole proved to be active against influenza viruses A/England 42/72, A/Bangkok 1/79 and A/fowl plague (FPV). The antiviral activities assayed by various methods varied from 90-99 per cent. No inhibition was found against influenza virus B/Leningrad 235/74 in vitro. Three dipyridamole derivatives were significantly active in tissue cultures against influenza virus A/England 42/72 and A/FPV. In white mice infected with influenza virus A/England 42/72 dipyridamole administered orally showed a protection rate of 62.5 per cent.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6127012

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  9 in total

1.  Inhibition of herpes simplex virus reactivation by dipyridamole.

Authors:  R B Tenser; A Gaydos; K A Hay
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages.

Authors:  J Szebeni; S M Wahl; M Popovic; L M Wahl; S Gartner; R L Fine; U Skaleric; R M Friedmann; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

Review 3.  Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections.

Authors:  Philip M Bath; Christopher M Coleman; Adam L Gordon; Wei Shen Lim; Andrew J Webb
Journal:  F1000Res       Date:  2021-07-05

4.  Dipyridamole reversibly inhibits mengovirus RNA replication.

Authors:  Cori L Fata-Hartley; Ann C Palmenberg
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 5.  Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

Authors:  Behnood Bikdeli; Mahesh V Madhavan; Aakriti Gupta; David Jimenez; John R Burton; Caroline Der Nigoghossian; Taylor Chuich; Shayan Nabavi Nouri; Isaac Dreyfus; Elissa Driggin; Sanjum Sethi; Kartik Sehgal; Saurav Chatterjee; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Laurent Bertoletti; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Alfonso J Tafur; Dominic P Francese; Jaya Batra; Anna Falanga; Kevin J Clerkin; Nir Uriel; Ajay Kirtane; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; Martin B Leon; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2020-05-30       Impact factor: 5.249

6.  Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.

Authors:  Kholoud F Aliter; Rami A Al-Horani
Journal:  Curr Pharm Des       Date:  2021       Impact factor: 3.116

Review 7.  Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction.

Authors:  Sandra Söderholm; Yu Fu; Lana Gaelings; Sergey Belanov; Laxman Yetukuri; Mikhail Berlinkov; Anton V Cheltsov; Simon Anders; Tero Aittokallio; Tuula A Nyman; Sampsa Matikainen; Denis E Kainov
Journal:  Viruses       Date:  2016-09-29       Impact factor: 5.048

Review 8.  Picornavirus inhibitors.

Authors:  L Carrasco
Journal:  Pharmacol Ther       Date:  1994       Impact factor: 12.310

9.  Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Authors:  Aslı Gelincik; Knut Brockow; Gülfem E Çelik; Inmaculada Doña; Cristobalina Mayorga; Antonino Romano; Özge Soyer; Marina Atanaskovic-Markovic; Annick Barbaud; Maria Jose Torres
Journal:  Allergy       Date:  2020-07-01       Impact factor: 14.710

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.